API Holdings, the parent company of PharmEasy, has received NCLT approval to merge its wholly owned subsidiary Docon Technologies with itself. While the move may appear to be a routine corporate restructuring, it could have wider significance given API Holdings’ existing control of listed Thyrocare Technologies and the possibility of a future reverse merger.
From Thyrocare Acquisition to Deleveraging
The story goes back to 2021, when API Holdings acquired a 71.22% stake in Thyrocare Technologies through its wholly owned subsidiary, Docon Technologies. This created a structure in which API Holdings controlled Thyrocare through Docon, with Docon effectively serving as the acquisition vehicle.
The acquisition, however, came with significant debt. API Holdings had borrowed to finance the transaction, increasing finance costs and putting additional pressure on the PharmEasy parent’s balance sheet. API subsequently began reducing its stake in Thyrocare as part of its deleveraging efforts. It sold around 10% of its Thyrocare holding in 2025 and another 9.9% in 2026, bringing its holding down to approximately 51.02%.
These stake sales, along with the company’s broader deleveraging efforts, helped API repay around ₹1,050 crore of debt. API Holdings has now become debt-free, removing a major financial burden that had followed the Thyrocare acquisition.
Why Is API Merging Docon?
The NCLT-approved merger removes one layer from the existing corporate structure. Once the scheme becomes effective, Docon Technologies will be merged into API Holdings and its 51.02% stake in Thyrocare will move directly to the parent company.
API Holdings will therefore directly hold its controlling stake in Thyrocare instead of holding it through Docon. Importantly, this is not a fresh acquisition of Thyrocare and there is no change in control. It is an internal restructuring designed to simplify the group’s corporate structure by removing an intermediate holding company.
Could This Set the Stage for a Reverse Merger?
This is where the development becomes more interesting. A potential reverse merger between API Holdings, or PharmEasy, and listed Thyrocare has previously been discussed by management as one of the strategic options being considered.
If such a transaction eventually takes place, listed Thyrocare could potentially become the listing vehicle for PharmEasy, giving API Holdings a route to the public markets through an already-listed company. However, the Docon merger does not mean that a reverse merger has been announced. It remains a potential strategic option and would depend on several conditions being met.
What Conditions Still Remain?
The most important conditions are related to profitability, debt and shareholder support. Management has previously indicated that API Holdings would need to become debt-free and achieve pre-tax profitability excluding Thyrocare before such a transaction could be considered.
API has now addressed the debt-free requirement. Another important factor would be obtaining support from Thyrocare’s minority shareholders, along with the necessary corporate, regulatory and other approvals.
This makes profitability the next major question. How close is API Holdings to achieving pre-tax profitability?
What About API Holdings’ Profitability?
API Holdings’ Q1 FY27 results show a significant improvement in its financial performance, although the company is not yet pre-tax profitable. Revenue increased from ₹1,591 crore in Q1 FY26 to ₹1,754 crore in Q1 FY27, representing approximately 10.22% YoY growth. On a QoQ basis, revenue declined by around 1.10%.
Gross margin also improved from ₹307 crore in Q1 FY26 to ₹375 crore in Q1 FY27, registering approximately 22% YoY growth. On a sequential basis, gross margin remained broadly stable, increasing by around 0.64%.
The bigger improvement came at the operating level. API Holdings reported EBITDA of ₹39 crore in Q1 FY27, compared with an EBITDA loss of ₹12 crore in Q1 FY26. The company had also reported an EBITDA profit of approximately ₹33 crore in the previous quarter.
The improvement extended to the profit-before-tax level. PBT loss narrowed from ₹145 crore in Q1 FY26 to ₹29 crore in Q1 FY27. One of the key reasons behind the improvement was the sharp reduction in finance costs, which declined from approximately ₹119 crore in Q1 FY26 to ₹55 crore in Q1 FY27.
As a result, EBITDA margin improved from -0.80% in Q1 FY26 to 2.20% in Q1 FY27. So, while API Holdings is moving in the right direction, it is still not pre-tax profitable. For a potential reverse merger, the important milestone is not simply positive EBITDA. API needs to move towards pre-tax profitability excluding Thyrocare.
Are the Conditions Becoming More Favourable?
The recent developments make the possibility more interesting. API Holdings has now become debt-free, removing one of the major financial hurdles. Its Q1 FY27 results also show a substantial improvement in operating performance, with positive EBITDA, a sharply reduced PBT loss and lower finance costs.
At the same time, the Docon merger simplifies the corporate structure and moves the 51.02% Thyrocare stake directly under API Holdings. This does not confirm a reverse merger, but it creates a cleaner corporate structure if API eventually decides to pursue such a transaction.
The key hurdle now is profitability. If API Holdings can move from a ₹29 crore PBT loss to pre-tax profitability excluding Thyrocare, another major condition could potentially be addressed. However, even then, a transaction would still require support from Thyrocare’s minority shareholders and the necessary regulatory and corporate approvals.
Conclusion
API Holdings is now debt-free, has simplified its structure by merging Docon, and is moving closer to the pre-tax profitability needed for a potential Thyrocare reverse merger.In,Q1 FY27 showed strong improvement, with ₹39 crore EBITDA and PBT loss narrowing to ₹29 crore, but the company is still not profitable.So, reverse merger/listing is not confirmed and remains one of the options on the table, subject to profitability, minority shareholder support and regulatory approvals.